Skip to main content
AIM Vaccine Co., Ltd. logo

AIM Vaccine Co., Ltd. — Investor Relations & Filings

Ticker · 6660 HKEX Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2025-03-18 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6660

About AIM Vaccine Co., Ltd.

https://www.aimbio.com

AIM Vaccine Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines for human use. The company's mission is to produce high-quality vaccines to safeguard global health. It holds a leading position among privately-owned vaccine enterprises in its primary market. The core product portfolio includes established vaccines such as Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Inactivated Hepatitis A Vaccine (Human Diploid Cell), and Meningococcal Polysaccharide Vaccine. AIM Vaccine is also a major global supplier of rabies vaccines, committed to leading technological advancements in this area. The company actively expands its pipeline, which features advanced candidates like the 13-valent pneumonia conjugate vaccine and iterative serum-free rabies vaccine, alongside strategic investments in mRNA technology, including an mRNA COVID-19 vaccine candidate.

Recent filings

Filing Released Lang Actions
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is titled “NOTICE OF BOARD MEETING” and contains an announcement of the date and agenda for an upcoming board meeting. It does not present any financial results, proxy materials, or changes in board composition; rather, it is a regulatory announcement calling a board meeting. None of the specific categories (e.g., 10-K, ER, MANG, PSI, DIV) fit this type of notice exactly. Therefore, it falls under the fallback category for general regulatory announcements (RNS).
2025-03-18 English
VOLUNTARY ANNOUNCEMENT - SIGNIFICANT DECREASE IN LOSS OF THE COMPANY'S RESULTS
Earnings Release Classification · 1% confidence The document is a voluntary announcement by AIM Vaccine Co., Ltd. providing unaudited preliminary consolidated revenue and net loss figures for the full year ended December 31, 2024, with key highlights only. It does not contain the full audited financial statements or management discussion in detail, nor is it a notice of a meeting or corporate action. This aligns with an initial earnings release rather than an annual report or other corporate filings. FY 2024
2025-03-17 English
VOLUNTARY ANNOUNCEMENT - ITERATIVE SERUM-FREE RABIES VACCINE: PHASE III CLINICAL TRIALS COMPLETED, PRODUCTION LICENSE OBTAINED AND APPLICATION FOR DRUG MARKETING REGISTRATION TO BE SUBMITTED
Regulatory Filings Classification · 1% confidence The document is a voluntary business update announcement by a Hong Kong‐listed vaccine company regarding completion of Phase III trials, obtaining a production license, and planned drug registration submission. It does not present financial results, share transactions, capital changes, annual or interim report content, legal proceedings, governance matters, or dividend information. It is not announcing a report publication but is a general corporate announcement. Therefore, it falls under the fallback category for miscellaneous regulatory filings: RNS.
2025-03-12 English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL OF THE ITERATIVE-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE APPROVED FURTHER CEMENTING OUR LEADING POSITION IN GLOBAL RABIES VACCINE INDUSTRY
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement published on the Hong Kong Stock Exchange regarding the approval of clinical trials for a new rabies vaccine. It does not present financial results, governance changes, share transactions, dividends, or other structured filings like annual or interim reports. It is not an investor presentation or a proxy document but rather a general business update. Therefore, it falls into the fallback category “Regulatory Filings” (RNS) for miscellaneous regulatory announcements.
2025-03-09 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a Next Day Disclosure Return (FF305) filed under the Hong Kong Stock Exchange rules to report a change in issued shares (new H share placement of 15.5 million shares) and confirm compliance with listing requirements. It is not an earnings release, audit report or AGM material; rather it specifically discloses the issuance of new shares under a general mandate, which falls squarely into “Share Issue/Capital Change.”
2025-03-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Exchange FF301 monthly return on movements in securities, covering authorized/registered share capital, issued shares, treasury shares, and share option movements for the month. This is a routine mandatory regulatory submission under HKEX Listing Rules, and does not fit specific categories like annual or interim reports, dividend notices, capital raising announcements, or M&A activity. Therefore it falls under the general “Regulatory Filings” category (RNS).
2025-03-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.